PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Pipeline portfolio PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Market segmentation by disease type • Rheumatoid arthritis • Osteoarthritis • Osteoporosis • Psoriatic arthritis • Ankylosing spondylitis • Fibromyalgia PART 08: Global rheumatoid arthritis drugs market • Market overview PART 09: Global osteoarthritis drugs market • Market overview PART 10: Global osteoporosis drugs market • Market overview PART 11: Global ankylosing spondylitis drugs market • Market overview PART 12: Global psoriatic arthritis drugs market • Market overview PART 13: Global fibromyalgia drugs market • Market overview PART 14: Market segmentation by type of molecule • Biologics • Small molecules PART 15: Market segmentation by route of administration • Parenteral • Topical • Oral PART 16: Geographical segmentation • Global musculoskeletal disorder therapeutics market by geography 2015-2020 • Musculoskeletal disorders therapeutics market in Americas • Musculoskeletal disorders therapeutics market in EMEA • Musculoskeletal disorders therapeutics market in APAC PART 17: Market drivers • High growth potential of mAbs • Unmet needs of therapeutics • Tentative approval of advanced drugs • Technological advancements in medical imaging • Combination therapies PART 18: Impact of drivers PART 19: Market challenges • Non-adherence to treatment regimen • Growing preference toward surgeries • Multiple patent expiries PART 20: Impact of drivers and challenges PART 21: Market trends • Focus on regenerative medicines • Ongoing active clinical trials for biosimilars • Growing focus toward abuse-resistant novel drugs PART 22: Vendor landscape • Competitive scenario PART 23: Key vendor analysis • AbbVie • Johnson & Johnson • Amgen • Pfizer • F. Hoffmann-La Roche • Eli Lilly • Other prominent vendors PART 24: Appendix • List of abbreviations PART 25: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key customer segments for musculoskeletal disorder therapeutics Exhibit 03: Impact of biologics on various sectors Exhibit 04: Pipeline portfolio: Global rheumatoid arthritis drugs market Exhibit 05: Pipeline portfolio: Global osteoarthritis drugs market Exhibit 06: Pipeline portfolio: Global osteoporosis drugs market Exhibit 07: Pipeline portfolio: Global psoriatic arthritis drugs market Exhibit 08: Pipeline portfolio: Global fibromyalgia drugs market Exhibit 09: Pipeline portfolio: Global ankylosing spondylitis drugs market Exhibit 10: Global musculoskeletal disorder therapeutics market 2015-2020 ($ billions) Exhibit 11: Patient assistance programs offered by companies Exhibit 12: CAM therapies for rheumatoid arthritis Exhibit 13: Five forces analysis Exhibit 14: Segmentation of global musculoskeletal disorder therapeutics market Exhibit 15: Segmentation of global musculoskeletal disorder therapeutics market by revenue 2015 Exhibit 16: Opportunities in rheumatoid arthritis drugs industry Exhibit 17: Global rheumatoid arthritis drugs market 2015-2020 ($ billions) Exhibit 18: Unmet medical needs with current osteoarthritis treatments Exhibit 19: Global osteoarthritis drugs market 2015-2020 ($ billions) Exhibit 20: Global osteoporosis drugs market 2015-2020 ($ billions) Exhibit 21: Global ankylosing spondylitis drugs market 2015-2020 ($ billions) Exhibit 22: Global psoriatic arthritis drugs market 2015-2020 ($ billions) Exhibit 23: Global fibromyalgia drugs market 2015-2020 ($ billions) Exhibit 24: Segmentation of global musculoskeletal disorder therapeutics market by type of molecules 2015 Exhibit 25: Segmentation of global musculoskeletal disorder therapeutics market by ROA 2015 Exhibit 26: Global musculoskeletal disorder therapeutics market by geography 2015-2020 Exhibit 27: Global musculoskeletal disorder therapeutics market segmentation by geography 2015-2020 ($ billions) Exhibit 28: Global share of musculoskeletal disorders therapeutics market by geography 2015 Exhibit 29: Global musculoskeletal disorder therapeutics market: Country analysis based on revenue and growth rate Exhibit 30: Musculoskeletal disorders therapeutics market in Americas 2015-2020 ($ billions) Exhibit 31: Musculoskeletal disorders therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 32: Musculoskeletal disorders therapeutics market in APAC 2015-2020 ($ billions) Exhibit 33: Few of the late-stage mAbs under development for various musculoskeletal disorders Exhibit 34: Impact of drivers Exhibit 35: Approval and patent expiries of top selling biologics Exhibit 36: Impact of drivers and challenges Exhibit 37: Key vendors ranking 2015 Exhibit 38: Geographical presence of key vendors Exhibit 39: Competitive scenario of global musculoskeletal disorder therapeutics market vendors 2015-2020 Exhibit 40: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions) Exhibit 41: AbbVie: Geographical segmentation of Humira 2015 Exhibit 42: AbbVie: Metrics analysis Exhibit 43: Key products in musculoskeletal disorders market with 2015 revenues Exhibit 44: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions) Exhibit 45: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions) Exhibit 46: Johnson & Johnson: YoY revenue and growth rate of Stelara 2013-2015 ($ billions) Exhibit 47: Johnson & Johnson: Metrics analysis Exhibit 48: Amgen: YoY revenue and growth rate of Enbrel (US and Canada) 2013-2015 ($ billions) Exhibit 49: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ billions) Exhibit 50: Amgen: Geographical segmentation of Prolia 2015 Exhibit 51: Amgen: Metrics analysis Exhibit 52: Key products in musculoskeletal disorders market with 2015 revenues Exhibit 53: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions) Exhibit 54: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions) Exhibit 55: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ billions) Exhibit 56: Pfizer: YoY revenue and growth rate of Xeljanz 2013-2015 ($ millions) Exhibit 57: Pfizer: Metrics analysis Exhibit 58: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan 2013-2015 ($ billions) Exhibit 59: F. Hoffmann-La Roche: Geographical segmentation of MabThera/Rituxan by revenue 2015 Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions) Exhibit 61: F. Hoffmann-La Roche: Geographical segmentation of Actemra/RoActemra by revenue 2015 Exhibit 62: F. Hoffmann-La Roche: Metrics analysis Exhibit 63: Eli Lilly: YoY revenue and growth rate of Cymbalta 2013-2015 ($ billions) Exhibit 64: Eli Lilly: YoY revenue and growth rate of Evista 2013-2015 ($ billions) Exhibit 65: Eli Lilly: Geographical segmentation of Evista 2015 Exhibit 66: Eli Lilly: YoY revenue and growth rate of Forteo 2013-2015 ($ billions) Exhibit 67: Eli Lilly: Geographical segmentation of Forteo 2015 Exhibit 68: Eli Lilly: Metrics analysis

AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche, Eli Lilly, 3SBio, AB Sciences, AbGenomics International, Ablynx, Adheron, Akron Molecules AG, Alder BioPharmaceuticals, Amgen Astellas BioPharma K.K. in Japan, Ampio Pharmaceuticals, Antares Medical Services, Astellas, AstraZeneca, Baxter, Biocad, Bioiberica, Boehringer Ingelheim, Bone Therapeutics, Can-Fite BioPharma, Celgene, Celltrion, Cellular Biomedicine, Cerapedics, ChemoCentryx, Chugai Pharmaceutical, Coherus Biosciences, Daiichi Sankyo, Dong-A ST, Edding Pharm, Eisai, Epirus, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gedeon Richter, Gilead Sciences, GlaxoSmithKline, Histogenics, IBSA Institut Biochimique, iCeutica, Iltoo Pharma, Incyte, Innovative Med Concepts, Iroko Pharmaceuticals, ISTO Technologies, KaloBios Pharmaceuticals, KAN Research Institute, Kang Stem Biotech, Kitov Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, MEDIPOST, Medivir, Merck, Mereo, Mesoblast, MOCHIDA PHARMACEUTICAL, MorphoSys, Morphotek, Mycenax, Neomed Institute, Novartis, Omeros, OrthoTrophix, Osteologix, OxyPharma, PFEnex, Philogen, PhytoHealth, Plexxikon, PLx Pharma, Protalex, Proximagen, Radius Health, Regeneron Pharmaceuticals, Samsung Bioepis, Samumed, Sandoz, Sanofi, SantoSolve AS, Steminent Biotherapeutics, Stempeutics Research, Taiwan Liposome Company, Takeda, Tarsa Therapeutics, Techfields Pharma, Tetec AG, TheraMAB, TiGenix, TissueGene, Tonix Pharmaceuticals, Translational Biosciences, UCB, Vericel, Vertex Pharmaceuticals, Vitaeris, Winston Laboratories, Zosano Pharma.